Global Cancer API Market

Cancer API Comprehensive Study by Degib (Sonidegib, Vismodegib), Tinib (Ponatinib, Brigatinib), Rafenib (Sorafenib, Regorafenib, Vemurafenib), Parib (Olaparib, Rucaparib, Niraparib) Players and Region - Global Market Outlook to 2028

Cancer API Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Cancer API Market Overview:
Cancer Active Pharmaceuticals Drugs (API) is the ingredient in medical drug use for cancer. Cancer is unregulated and disordered cell development. There are five main API molecule categories including Tinib, Rafenib, Parib, Lisib, Degib, and Ciclib. Rising demand for small molecule drugs, the improved incidence of cancer as well as the entrance of new active pharmaceutical ingredients (API) will help to expand the global cancer API market. Furthermore, the initiation of smart healthcare is pavement the method for new APIs including cancer APIs.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Upsurging Adoption of Offshore Manufacturing in Pharmaceutical Products Manufacturing and Introduction to highly Advanced and Safe Active Pharmaceutical Ingredients (APIs)

Market Growth Drivers:
Growing Instances of Cancer Patients across the Globe and Increasing Demand for Small Molecule Drugs

Challenges:
Growing Hourly Wages and Per Day Labor Costs for Skilled Workers and Continues Technological Advancements may lead to Threat of Substitutes

Restraints:
Cancer API might Possess Few Side Effects leading to Hamper Overall Business Growth and Comparatively Higher Production Cost than the Conventional Pharmaceutical Products

Opportunities:
Continues Research and Development in the Active Pharmaceutical Product Manufacturing and Robust Investments in Enhancing the Healthcare Infrastructure across the Globe

Competitive Landscape:
The Cancer API market is fragmented market due to the presence of various players. The players are focusing on investing in research and development activities, enhancing their technology capabilities, improving the accuracy and speed of cancer diagnosis, and developing more effective and personalized cancer treatments. Additionally, they are increasingly leveraging data analytics and AI to provide more personalized and efficient services to patients and healthcare providers. Further, the companies are also planning strategic activities such as partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.
Some of the key players profiled in the report are Exelixis Inc. (United States), Pfizer Inc. (United States), Eisai Ltd. (Japan), Bristol-Myers Squibb (United States), AbbVie Inc. (United States), F. Hoffman La Roche (Switzerland), AstraZeneca PLC (United Kingdom), Novartis AG (Switzerland), Bayer AG (Germany), Ariad Pharmaceuticals Inc. (Takeda) (United States), Boehringer Ingelheim (Germany) and Celgene (United States). Additionally, following companies can also be profiled that are part of our coverage like Clovis Oncology (United States), Eli Lilly & Company (United States), Gilead Lifesciences Inc. (United States), Incyte Corporation (United States), Puma Biotech (United States) and TESARO, Inc. (United States). Analyst at AMA Research see United States and European Players to retain maximum share of Global Cancer API market by 2028. Considering Market by Degib, the sub-segment i.e. Sonidegib will boost the Cancer API market. Considering Market by Tinib, the sub-segment i.e. Ponatinib will boost the Cancer API market. Considering Market by Rafenib, the sub-segment i.e. Sorafenib will boost the Cancer API market. Considering Market by Parib, the sub-segment i.e. Olaparib will boost the Cancer API market.

Latest Market Insights:
In September 2022, PAG-led API Platform acquired controlling stake in Optimus, a leading manufacturer of active pharmaceutical ingredients (APIs). It aimed to enhance PAG's presence in the global API market and expands Optimus' product portfolio and manufacturing capabilities. Further, the acquisition is expected to drive innovation in the API industry by combining the expertise of PAG and Optimus and leveraging the growing demand for APIs globally.

In April 2022, PharmaZell merged with Novasep to manufacture new CDMO, API. Novasep, a France-based Contract Manufacturing Organization (CMO). The merger is expected to create significant synergies and enable the new company to expand its customer base and increase its manufacturing capacity.

The European Parliament has executed a resolution during its plenary session in Strasbourg. The primary objective of this resolution is to prohibit/control the scope of pharmaceutical companies’ to avoid the obligation. Thus, the existing law is imposed on them to develop and investigate drugs for children. Nowadays, these drug manufacturers can ask for renunciation from the obligations to investigate the potential benefit of a drug for the children, if the adult cancer for which the drug was originally developed does not exist in children.

What Can be Explored with the Cancer API Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Cancer API Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Cancer API
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cancer API market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cancer API market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Cancer API Manufacturers, Cancer API Distributors and Traders, Research and Development (R&D) Companies, Government Research Institutes and Academic Institutes and Universities.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Degib
  • Sonidegib
  • Vismodegib

By Tinib
  • Ponatinib
  • Brigatinib

By Rafenib
  • Sorafenib
  • Regorafenib
  • Vemurafenib

By Parib
  • Olaparib
  • Rucaparib
  • Niraparib

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Instances of Cancer Patients across the Globe
      • 3.2.2. Increasing Demand for Small Molecule Drugs
    • 3.3. Market Challenges
      • 3.3.1. Growing Hourly Wages and Per Day Labor Costs for Skilled Workers
      • 3.3.2. Continues Technological Advancements may lead to Threat of Substitutes
    • 3.4. Market Trends
      • 3.4.1. Upsurging Adoption of Offshore Manufacturing in Pharmaceutical Products Manufacturing
      • 3.4.2. Introduction to highly Advanced and Safe Active Pharmaceutical Ingredients (APIs)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer API, by Degib, Tinib, Rafenib, Parib and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer API (Value)
      • 5.2.1. Global Cancer API by: Degib (Value)
        • 5.2.1.1. Sonidegib
        • 5.2.1.2. Vismodegib
      • 5.2.2. Global Cancer API by: Tinib (Value)
        • 5.2.2.1. Ponatinib
        • 5.2.2.2. Brigatinib
      • 5.2.3. Global Cancer API by: Rafenib (Value)
        • 5.2.3.1. Sorafenib
        • 5.2.3.2. Regorafenib
        • 5.2.3.3. Vemurafenib
      • 5.2.4. Global Cancer API by: Parib (Value)
        • 5.2.4.1. Olaparib
        • 5.2.4.2. Rucaparib
        • 5.2.4.3. Niraparib
      • 5.2.5. Global Cancer API Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cancer API (Volume)
      • 5.3.1. Global Cancer API by: Degib (Volume)
        • 5.3.1.1. Sonidegib
        • 5.3.1.2. Vismodegib
      • 5.3.2. Global Cancer API by: Tinib (Volume)
        • 5.3.2.1. Ponatinib
        • 5.3.2.2. Brigatinib
      • 5.3.3. Global Cancer API by: Rafenib (Volume)
        • 5.3.3.1. Sorafenib
        • 5.3.3.2. Regorafenib
        • 5.3.3.3. Vemurafenib
      • 5.3.4. Global Cancer API by: Parib (Volume)
        • 5.3.4.1. Olaparib
        • 5.3.4.2. Rucaparib
        • 5.3.4.3. Niraparib
      • 5.3.5. Global Cancer API Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Cancer API (Price)
  • 6. Cancer API: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Exelixis Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eisai Ltd. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Myers Squibb (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffman La Roche (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca PLC (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ariad Pharmaceuticals Inc. (Takeda) (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Boehringer Ingelheim (Germany)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Celgene (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Cancer API Sale, by Degib, Tinib, Rafenib, Parib and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer API (Value)
      • 7.2.1. Global Cancer API by: Degib (Value)
        • 7.2.1.1. Sonidegib
        • 7.2.1.2. Vismodegib
      • 7.2.2. Global Cancer API by: Tinib (Value)
        • 7.2.2.1. Ponatinib
        • 7.2.2.2. Brigatinib
      • 7.2.3. Global Cancer API by: Rafenib (Value)
        • 7.2.3.1. Sorafenib
        • 7.2.3.2. Regorafenib
        • 7.2.3.3. Vemurafenib
      • 7.2.4. Global Cancer API by: Parib (Value)
        • 7.2.4.1. Olaparib
        • 7.2.4.2. Rucaparib
        • 7.2.4.3. Niraparib
      • 7.2.5. Global Cancer API Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cancer API (Volume)
      • 7.3.1. Global Cancer API by: Degib (Volume)
        • 7.3.1.1. Sonidegib
        • 7.3.1.2. Vismodegib
      • 7.3.2. Global Cancer API by: Tinib (Volume)
        • 7.3.2.1. Ponatinib
        • 7.3.2.2. Brigatinib
      • 7.3.3. Global Cancer API by: Rafenib (Volume)
        • 7.3.3.1. Sorafenib
        • 7.3.3.2. Regorafenib
        • 7.3.3.3. Vemurafenib
      • 7.3.4. Global Cancer API by: Parib (Volume)
        • 7.3.4.1. Olaparib
        • 7.3.4.2. Rucaparib
        • 7.3.4.3. Niraparib
      • 7.3.5. Global Cancer API Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Cancer API (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer API: by Degib(USD Million)
  • Table 2. Cancer API Sonidegib , by Region USD Million (2017-2022)
  • Table 3. Cancer API Vismodegib , by Region USD Million (2017-2022)
  • Table 4. Cancer API: by Tinib(USD Million)
  • Table 5. Cancer API Ponatinib , by Region USD Million (2017-2022)
  • Table 6. Cancer API Brigatinib , by Region USD Million (2017-2022)
  • Table 7. Cancer API: by Rafenib(USD Million)
  • Table 8. Cancer API Sorafenib , by Region USD Million (2017-2022)
  • Table 9. Cancer API Regorafenib , by Region USD Million (2017-2022)
  • Table 10. Cancer API Vemurafenib , by Region USD Million (2017-2022)
  • Table 11. Cancer API: by Parib(USD Million)
  • Table 12. Cancer API Olaparib , by Region USD Million (2017-2022)
  • Table 13. Cancer API Rucaparib , by Region USD Million (2017-2022)
  • Table 14. Cancer API Niraparib , by Region USD Million (2017-2022)
  • Table 15. South America Cancer API, by Country USD Million (2017-2022)
  • Table 16. South America Cancer API, by Degib USD Million (2017-2022)
  • Table 17. South America Cancer API, by Tinib USD Million (2017-2022)
  • Table 18. South America Cancer API, by Rafenib USD Million (2017-2022)
  • Table 19. South America Cancer API, by Parib USD Million (2017-2022)
  • Table 20. Brazil Cancer API, by Degib USD Million (2017-2022)
  • Table 21. Brazil Cancer API, by Tinib USD Million (2017-2022)
  • Table 22. Brazil Cancer API, by Rafenib USD Million (2017-2022)
  • Table 23. Brazil Cancer API, by Parib USD Million (2017-2022)
  • Table 24. Argentina Cancer API, by Degib USD Million (2017-2022)
  • Table 25. Argentina Cancer API, by Tinib USD Million (2017-2022)
  • Table 26. Argentina Cancer API, by Rafenib USD Million (2017-2022)
  • Table 27. Argentina Cancer API, by Parib USD Million (2017-2022)
  • Table 28. Rest of South America Cancer API, by Degib USD Million (2017-2022)
  • Table 29. Rest of South America Cancer API, by Tinib USD Million (2017-2022)
  • Table 30. Rest of South America Cancer API, by Rafenib USD Million (2017-2022)
  • Table 31. Rest of South America Cancer API, by Parib USD Million (2017-2022)
  • Table 32. Asia Pacific Cancer API, by Country USD Million (2017-2022)
  • Table 33. Asia Pacific Cancer API, by Degib USD Million (2017-2022)
  • Table 34. Asia Pacific Cancer API, by Tinib USD Million (2017-2022)
  • Table 35. Asia Pacific Cancer API, by Rafenib USD Million (2017-2022)
  • Table 36. Asia Pacific Cancer API, by Parib USD Million (2017-2022)
  • Table 37. China Cancer API, by Degib USD Million (2017-2022)
  • Table 38. China Cancer API, by Tinib USD Million (2017-2022)
  • Table 39. China Cancer API, by Rafenib USD Million (2017-2022)
  • Table 40. China Cancer API, by Parib USD Million (2017-2022)
  • Table 41. Japan Cancer API, by Degib USD Million (2017-2022)
  • Table 42. Japan Cancer API, by Tinib USD Million (2017-2022)
  • Table 43. Japan Cancer API, by Rafenib USD Million (2017-2022)
  • Table 44. Japan Cancer API, by Parib USD Million (2017-2022)
  • Table 45. India Cancer API, by Degib USD Million (2017-2022)
  • Table 46. India Cancer API, by Tinib USD Million (2017-2022)
  • Table 47. India Cancer API, by Rafenib USD Million (2017-2022)
  • Table 48. India Cancer API, by Parib USD Million (2017-2022)
  • Table 49. South Korea Cancer API, by Degib USD Million (2017-2022)
  • Table 50. South Korea Cancer API, by Tinib USD Million (2017-2022)
  • Table 51. South Korea Cancer API, by Rafenib USD Million (2017-2022)
  • Table 52. South Korea Cancer API, by Parib USD Million (2017-2022)
  • Table 53. Taiwan Cancer API, by Degib USD Million (2017-2022)
  • Table 54. Taiwan Cancer API, by Tinib USD Million (2017-2022)
  • Table 55. Taiwan Cancer API, by Rafenib USD Million (2017-2022)
  • Table 56. Taiwan Cancer API, by Parib USD Million (2017-2022)
  • Table 57. Australia Cancer API, by Degib USD Million (2017-2022)
  • Table 58. Australia Cancer API, by Tinib USD Million (2017-2022)
  • Table 59. Australia Cancer API, by Rafenib USD Million (2017-2022)
  • Table 60. Australia Cancer API, by Parib USD Million (2017-2022)
  • Table 61. Rest of Asia-Pacific Cancer API, by Degib USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Cancer API, by Tinib USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Cancer API, by Rafenib USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Cancer API, by Parib USD Million (2017-2022)
  • Table 65. Europe Cancer API, by Country USD Million (2017-2022)
  • Table 66. Europe Cancer API, by Degib USD Million (2017-2022)
  • Table 67. Europe Cancer API, by Tinib USD Million (2017-2022)
  • Table 68. Europe Cancer API, by Rafenib USD Million (2017-2022)
  • Table 69. Europe Cancer API, by Parib USD Million (2017-2022)
  • Table 70. Germany Cancer API, by Degib USD Million (2017-2022)
  • Table 71. Germany Cancer API, by Tinib USD Million (2017-2022)
  • Table 72. Germany Cancer API, by Rafenib USD Million (2017-2022)
  • Table 73. Germany Cancer API, by Parib USD Million (2017-2022)
  • Table 74. France Cancer API, by Degib USD Million (2017-2022)
  • Table 75. France Cancer API, by Tinib USD Million (2017-2022)
  • Table 76. France Cancer API, by Rafenib USD Million (2017-2022)
  • Table 77. France Cancer API, by Parib USD Million (2017-2022)
  • Table 78. Italy Cancer API, by Degib USD Million (2017-2022)
  • Table 79. Italy Cancer API, by Tinib USD Million (2017-2022)
  • Table 80. Italy Cancer API, by Rafenib USD Million (2017-2022)
  • Table 81. Italy Cancer API, by Parib USD Million (2017-2022)
  • Table 82. United Kingdom Cancer API, by Degib USD Million (2017-2022)
  • Table 83. United Kingdom Cancer API, by Tinib USD Million (2017-2022)
  • Table 84. United Kingdom Cancer API, by Rafenib USD Million (2017-2022)
  • Table 85. United Kingdom Cancer API, by Parib USD Million (2017-2022)
  • Table 86. Netherlands Cancer API, by Degib USD Million (2017-2022)
  • Table 87. Netherlands Cancer API, by Tinib USD Million (2017-2022)
  • Table 88. Netherlands Cancer API, by Rafenib USD Million (2017-2022)
  • Table 89. Netherlands Cancer API, by Parib USD Million (2017-2022)
  • Table 90. Rest of Europe Cancer API, by Degib USD Million (2017-2022)
  • Table 91. Rest of Europe Cancer API, by Tinib USD Million (2017-2022)
  • Table 92. Rest of Europe Cancer API, by Rafenib USD Million (2017-2022)
  • Table 93. Rest of Europe Cancer API, by Parib USD Million (2017-2022)
  • Table 94. MEA Cancer API, by Country USD Million (2017-2022)
  • Table 95. MEA Cancer API, by Degib USD Million (2017-2022)
  • Table 96. MEA Cancer API, by Tinib USD Million (2017-2022)
  • Table 97. MEA Cancer API, by Rafenib USD Million (2017-2022)
  • Table 98. MEA Cancer API, by Parib USD Million (2017-2022)
  • Table 99. Middle East Cancer API, by Degib USD Million (2017-2022)
  • Table 100. Middle East Cancer API, by Tinib USD Million (2017-2022)
  • Table 101. Middle East Cancer API, by Rafenib USD Million (2017-2022)
  • Table 102. Middle East Cancer API, by Parib USD Million (2017-2022)
  • Table 103. Africa Cancer API, by Degib USD Million (2017-2022)
  • Table 104. Africa Cancer API, by Tinib USD Million (2017-2022)
  • Table 105. Africa Cancer API, by Rafenib USD Million (2017-2022)
  • Table 106. Africa Cancer API, by Parib USD Million (2017-2022)
  • Table 107. North America Cancer API, by Country USD Million (2017-2022)
  • Table 108. North America Cancer API, by Degib USD Million (2017-2022)
  • Table 109. North America Cancer API, by Tinib USD Million (2017-2022)
  • Table 110. North America Cancer API, by Rafenib USD Million (2017-2022)
  • Table 111. North America Cancer API, by Parib USD Million (2017-2022)
  • Table 112. United States Cancer API, by Degib USD Million (2017-2022)
  • Table 113. United States Cancer API, by Tinib USD Million (2017-2022)
  • Table 114. United States Cancer API, by Rafenib USD Million (2017-2022)
  • Table 115. United States Cancer API, by Parib USD Million (2017-2022)
  • Table 116. Canada Cancer API, by Degib USD Million (2017-2022)
  • Table 117. Canada Cancer API, by Tinib USD Million (2017-2022)
  • Table 118. Canada Cancer API, by Rafenib USD Million (2017-2022)
  • Table 119. Canada Cancer API, by Parib USD Million (2017-2022)
  • Table 120. Mexico Cancer API, by Degib USD Million (2017-2022)
  • Table 121. Mexico Cancer API, by Tinib USD Million (2017-2022)
  • Table 122. Mexico Cancer API, by Rafenib USD Million (2017-2022)
  • Table 123. Mexico Cancer API, by Parib USD Million (2017-2022)
  • Table 124. Cancer API Sales: by Degib(K Tons)
  • Table 125. Cancer API Sales Sonidegib , by Region K Tons (2017-2022)
  • Table 126. Cancer API Sales Vismodegib , by Region K Tons (2017-2022)
  • Table 127. Cancer API Sales: by Tinib(K Tons)
  • Table 128. Cancer API Sales Ponatinib , by Region K Tons (2017-2022)
  • Table 129. Cancer API Sales Brigatinib , by Region K Tons (2017-2022)
  • Table 130. Cancer API Sales: by Rafenib(K Tons)
  • Table 131. Cancer API Sales Sorafenib , by Region K Tons (2017-2022)
  • Table 132. Cancer API Sales Regorafenib , by Region K Tons (2017-2022)
  • Table 133. Cancer API Sales Vemurafenib , by Region K Tons (2017-2022)
  • Table 134. Cancer API Sales: by Parib(K Tons)
  • Table 135. Cancer API Sales Olaparib , by Region K Tons (2017-2022)
  • Table 136. Cancer API Sales Rucaparib , by Region K Tons (2017-2022)
  • Table 137. Cancer API Sales Niraparib , by Region K Tons (2017-2022)
  • Table 138. South America Cancer API Sales, by Country K Tons (2017-2022)
  • Table 139. South America Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 140. South America Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 141. South America Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 142. South America Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 143. Brazil Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 144. Brazil Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 145. Brazil Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 146. Brazil Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 147. Argentina Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 148. Argentina Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 149. Argentina Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 150. Argentina Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 151. Rest of South America Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 152. Rest of South America Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 153. Rest of South America Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 154. Rest of South America Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 155. Asia Pacific Cancer API Sales, by Country K Tons (2017-2022)
  • Table 156. Asia Pacific Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 157. Asia Pacific Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 158. Asia Pacific Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 159. Asia Pacific Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 160. China Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 161. China Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 162. China Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 163. China Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 164. Japan Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 165. Japan Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 166. Japan Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 167. Japan Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 168. India Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 169. India Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 170. India Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 171. India Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 172. South Korea Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 173. South Korea Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 174. South Korea Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 175. South Korea Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 176. Taiwan Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 177. Taiwan Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 178. Taiwan Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 179. Taiwan Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 180. Australia Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 181. Australia Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 182. Australia Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 183. Australia Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 184. Rest of Asia-Pacific Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 185. Rest of Asia-Pacific Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 186. Rest of Asia-Pacific Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 187. Rest of Asia-Pacific Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 188. Europe Cancer API Sales, by Country K Tons (2017-2022)
  • Table 189. Europe Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 190. Europe Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 191. Europe Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 192. Europe Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 193. Germany Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 194. Germany Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 195. Germany Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 196. Germany Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 197. France Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 198. France Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 199. France Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 200. France Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 201. Italy Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 202. Italy Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 203. Italy Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 204. Italy Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 205. United Kingdom Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 206. United Kingdom Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 207. United Kingdom Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 208. United Kingdom Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 209. Netherlands Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 210. Netherlands Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 211. Netherlands Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 212. Netherlands Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 213. Rest of Europe Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 214. Rest of Europe Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 215. Rest of Europe Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 216. Rest of Europe Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 217. MEA Cancer API Sales, by Country K Tons (2017-2022)
  • Table 218. MEA Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 219. MEA Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 220. MEA Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 221. MEA Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 222. Middle East Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 223. Middle East Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 224. Middle East Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 225. Middle East Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 226. Africa Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 227. Africa Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 228. Africa Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 229. Africa Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 230. North America Cancer API Sales, by Country K Tons (2017-2022)
  • Table 231. North America Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 232. North America Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 233. North America Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 234. North America Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 235. United States Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 236. United States Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 237. United States Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 238. United States Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 239. Canada Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 240. Canada Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 241. Canada Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 242. Canada Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 243. Mexico Cancer API Sales, by Degib K Tons (2017-2022)
  • Table 244. Mexico Cancer API Sales, by Tinib K Tons (2017-2022)
  • Table 245. Mexico Cancer API Sales, by Rafenib K Tons (2017-2022)
  • Table 246. Mexico Cancer API Sales, by Parib K Tons (2017-2022)
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Cancer API: by Degib(USD Million)
  • Table 260. Cancer API Sonidegib , by Region USD Million (2023-2028)
  • Table 261. Cancer API Vismodegib , by Region USD Million (2023-2028)
  • Table 262. Cancer API: by Tinib(USD Million)
  • Table 263. Cancer API Ponatinib , by Region USD Million (2023-2028)
  • Table 264. Cancer API Brigatinib , by Region USD Million (2023-2028)
  • Table 265. Cancer API: by Rafenib(USD Million)
  • Table 266. Cancer API Sorafenib , by Region USD Million (2023-2028)
  • Table 267. Cancer API Regorafenib , by Region USD Million (2023-2028)
  • Table 268. Cancer API Vemurafenib , by Region USD Million (2023-2028)
  • Table 269. Cancer API: by Parib(USD Million)
  • Table 270. Cancer API Olaparib , by Region USD Million (2023-2028)
  • Table 271. Cancer API Rucaparib , by Region USD Million (2023-2028)
  • Table 272. Cancer API Niraparib , by Region USD Million (2023-2028)
  • Table 273. South America Cancer API, by Country USD Million (2023-2028)
  • Table 274. South America Cancer API, by Degib USD Million (2023-2028)
  • Table 275. South America Cancer API, by Tinib USD Million (2023-2028)
  • Table 276. South America Cancer API, by Rafenib USD Million (2023-2028)
  • Table 277. South America Cancer API, by Parib USD Million (2023-2028)
  • Table 278. Brazil Cancer API, by Degib USD Million (2023-2028)
  • Table 279. Brazil Cancer API, by Tinib USD Million (2023-2028)
  • Table 280. Brazil Cancer API, by Rafenib USD Million (2023-2028)
  • Table 281. Brazil Cancer API, by Parib USD Million (2023-2028)
  • Table 282. Argentina Cancer API, by Degib USD Million (2023-2028)
  • Table 283. Argentina Cancer API, by Tinib USD Million (2023-2028)
  • Table 284. Argentina Cancer API, by Rafenib USD Million (2023-2028)
  • Table 285. Argentina Cancer API, by Parib USD Million (2023-2028)
  • Table 286. Rest of South America Cancer API, by Degib USD Million (2023-2028)
  • Table 287. Rest of South America Cancer API, by Tinib USD Million (2023-2028)
  • Table 288. Rest of South America Cancer API, by Rafenib USD Million (2023-2028)
  • Table 289. Rest of South America Cancer API, by Parib USD Million (2023-2028)
  • Table 290. Asia Pacific Cancer API, by Country USD Million (2023-2028)
  • Table 291. Asia Pacific Cancer API, by Degib USD Million (2023-2028)
  • Table 292. Asia Pacific Cancer API, by Tinib USD Million (2023-2028)
  • Table 293. Asia Pacific Cancer API, by Rafenib USD Million (2023-2028)
  • Table 294. Asia Pacific Cancer API, by Parib USD Million (2023-2028)
  • Table 295. China Cancer API, by Degib USD Million (2023-2028)
  • Table 296. China Cancer API, by Tinib USD Million (2023-2028)
  • Table 297. China Cancer API, by Rafenib USD Million (2023-2028)
  • Table 298. China Cancer API, by Parib USD Million (2023-2028)
  • Table 299. Japan Cancer API, by Degib USD Million (2023-2028)
  • Table 300. Japan Cancer API, by Tinib USD Million (2023-2028)
  • Table 301. Japan Cancer API, by Rafenib USD Million (2023-2028)
  • Table 302. Japan Cancer API, by Parib USD Million (2023-2028)
  • Table 303. India Cancer API, by Degib USD Million (2023-2028)
  • Table 304. India Cancer API, by Tinib USD Million (2023-2028)
  • Table 305. India Cancer API, by Rafenib USD Million (2023-2028)
  • Table 306. India Cancer API, by Parib USD Million (2023-2028)
  • Table 307. South Korea Cancer API, by Degib USD Million (2023-2028)
  • Table 308. South Korea Cancer API, by Tinib USD Million (2023-2028)
  • Table 309. South Korea Cancer API, by Rafenib USD Million (2023-2028)
  • Table 310. South Korea Cancer API, by Parib USD Million (2023-2028)
  • Table 311. Taiwan Cancer API, by Degib USD Million (2023-2028)
  • Table 312. Taiwan Cancer API, by Tinib USD Million (2023-2028)
  • Table 313. Taiwan Cancer API, by Rafenib USD Million (2023-2028)
  • Table 314. Taiwan Cancer API, by Parib USD Million (2023-2028)
  • Table 315. Australia Cancer API, by Degib USD Million (2023-2028)
  • Table 316. Australia Cancer API, by Tinib USD Million (2023-2028)
  • Table 317. Australia Cancer API, by Rafenib USD Million (2023-2028)
  • Table 318. Australia Cancer API, by Parib USD Million (2023-2028)
  • Table 319. Rest of Asia-Pacific Cancer API, by Degib USD Million (2023-2028)
  • Table 320. Rest of Asia-Pacific Cancer API, by Tinib USD Million (2023-2028)
  • Table 321. Rest of Asia-Pacific Cancer API, by Rafenib USD Million (2023-2028)
  • Table 322. Rest of Asia-Pacific Cancer API, by Parib USD Million (2023-2028)
  • Table 323. Europe Cancer API, by Country USD Million (2023-2028)
  • Table 324. Europe Cancer API, by Degib USD Million (2023-2028)
  • Table 325. Europe Cancer API, by Tinib USD Million (2023-2028)
  • Table 326. Europe Cancer API, by Rafenib USD Million (2023-2028)
  • Table 327. Europe Cancer API, by Parib USD Million (2023-2028)
  • Table 328. Germany Cancer API, by Degib USD Million (2023-2028)
  • Table 329. Germany Cancer API, by Tinib USD Million (2023-2028)
  • Table 330. Germany Cancer API, by Rafenib USD Million (2023-2028)
  • Table 331. Germany Cancer API, by Parib USD Million (2023-2028)
  • Table 332. France Cancer API, by Degib USD Million (2023-2028)
  • Table 333. France Cancer API, by Tinib USD Million (2023-2028)
  • Table 334. France Cancer API, by Rafenib USD Million (2023-2028)
  • Table 335. France Cancer API, by Parib USD Million (2023-2028)
  • Table 336. Italy Cancer API, by Degib USD Million (2023-2028)
  • Table 337. Italy Cancer API, by Tinib USD Million (2023-2028)
  • Table 338. Italy Cancer API, by Rafenib USD Million (2023-2028)
  • Table 339. Italy Cancer API, by Parib USD Million (2023-2028)
  • Table 340. United Kingdom Cancer API, by Degib USD Million (2023-2028)
  • Table 341. United Kingdom Cancer API, by Tinib USD Million (2023-2028)
  • Table 342. United Kingdom Cancer API, by Rafenib USD Million (2023-2028)
  • Table 343. United Kingdom Cancer API, by Parib USD Million (2023-2028)
  • Table 344. Netherlands Cancer API, by Degib USD Million (2023-2028)
  • Table 345. Netherlands Cancer API, by Tinib USD Million (2023-2028)
  • Table 346. Netherlands Cancer API, by Rafenib USD Million (2023-2028)
  • Table 347. Netherlands Cancer API, by Parib USD Million (2023-2028)
  • Table 348. Rest of Europe Cancer API, by Degib USD Million (2023-2028)
  • Table 349. Rest of Europe Cancer API, by Tinib USD Million (2023-2028)
  • Table 350. Rest of Europe Cancer API, by Rafenib USD Million (2023-2028)
  • Table 351. Rest of Europe Cancer API, by Parib USD Million (2023-2028)
  • Table 352. MEA Cancer API, by Country USD Million (2023-2028)
  • Table 353. MEA Cancer API, by Degib USD Million (2023-2028)
  • Table 354. MEA Cancer API, by Tinib USD Million (2023-2028)
  • Table 355. MEA Cancer API, by Rafenib USD Million (2023-2028)
  • Table 356. MEA Cancer API, by Parib USD Million (2023-2028)
  • Table 357. Middle East Cancer API, by Degib USD Million (2023-2028)
  • Table 358. Middle East Cancer API, by Tinib USD Million (2023-2028)
  • Table 359. Middle East Cancer API, by Rafenib USD Million (2023-2028)
  • Table 360. Middle East Cancer API, by Parib USD Million (2023-2028)
  • Table 361. Africa Cancer API, by Degib USD Million (2023-2028)
  • Table 362. Africa Cancer API, by Tinib USD Million (2023-2028)
  • Table 363. Africa Cancer API, by Rafenib USD Million (2023-2028)
  • Table 364. Africa Cancer API, by Parib USD Million (2023-2028)
  • Table 365. North America Cancer API, by Country USD Million (2023-2028)
  • Table 366. North America Cancer API, by Degib USD Million (2023-2028)
  • Table 367. North America Cancer API, by Tinib USD Million (2023-2028)
  • Table 368. North America Cancer API, by Rafenib USD Million (2023-2028)
  • Table 369. North America Cancer API, by Parib USD Million (2023-2028)
  • Table 370. United States Cancer API, by Degib USD Million (2023-2028)
  • Table 371. United States Cancer API, by Tinib USD Million (2023-2028)
  • Table 372. United States Cancer API, by Rafenib USD Million (2023-2028)
  • Table 373. United States Cancer API, by Parib USD Million (2023-2028)
  • Table 374. Canada Cancer API, by Degib USD Million (2023-2028)
  • Table 375. Canada Cancer API, by Tinib USD Million (2023-2028)
  • Table 376. Canada Cancer API, by Rafenib USD Million (2023-2028)
  • Table 377. Canada Cancer API, by Parib USD Million (2023-2028)
  • Table 378. Mexico Cancer API, by Degib USD Million (2023-2028)
  • Table 379. Mexico Cancer API, by Tinib USD Million (2023-2028)
  • Table 380. Mexico Cancer API, by Rafenib USD Million (2023-2028)
  • Table 381. Mexico Cancer API, by Parib USD Million (2023-2028)
  • Table 382. Cancer API Sales: by Degib(K Tons)
  • Table 383. Cancer API Sales Sonidegib , by Region K Tons (2023-2028)
  • Table 384. Cancer API Sales Vismodegib , by Region K Tons (2023-2028)
  • Table 385. Cancer API Sales: by Tinib(K Tons)
  • Table 386. Cancer API Sales Ponatinib , by Region K Tons (2023-2028)
  • Table 387. Cancer API Sales Brigatinib , by Region K Tons (2023-2028)
  • Table 388. Cancer API Sales: by Rafenib(K Tons)
  • Table 389. Cancer API Sales Sorafenib , by Region K Tons (2023-2028)
  • Table 390. Cancer API Sales Regorafenib , by Region K Tons (2023-2028)
  • Table 391. Cancer API Sales Vemurafenib , by Region K Tons (2023-2028)
  • Table 392. Cancer API Sales: by Parib(K Tons)
  • Table 393. Cancer API Sales Olaparib , by Region K Tons (2023-2028)
  • Table 394. Cancer API Sales Rucaparib , by Region K Tons (2023-2028)
  • Table 395. Cancer API Sales Niraparib , by Region K Tons (2023-2028)
  • Table 396. South America Cancer API Sales, by Country K Tons (2023-2028)
  • Table 397. South America Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 398. South America Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 399. South America Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 400. South America Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 401. Brazil Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 402. Brazil Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 403. Brazil Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 404. Brazil Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 405. Argentina Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 406. Argentina Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 407. Argentina Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 408. Argentina Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 409. Rest of South America Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 410. Rest of South America Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 411. Rest of South America Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 412. Rest of South America Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 413. Asia Pacific Cancer API Sales, by Country K Tons (2023-2028)
  • Table 414. Asia Pacific Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 415. Asia Pacific Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 416. Asia Pacific Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 417. Asia Pacific Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 418. China Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 419. China Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 420. China Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 421. China Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 422. Japan Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 423. Japan Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 424. Japan Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 425. Japan Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 426. India Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 427. India Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 428. India Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 429. India Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 430. South Korea Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 431. South Korea Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 432. South Korea Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 433. South Korea Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 434. Taiwan Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 435. Taiwan Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 436. Taiwan Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 437. Taiwan Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 438. Australia Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 439. Australia Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 440. Australia Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 441. Australia Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 442. Rest of Asia-Pacific Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 443. Rest of Asia-Pacific Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 444. Rest of Asia-Pacific Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 445. Rest of Asia-Pacific Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 446. Europe Cancer API Sales, by Country K Tons (2023-2028)
  • Table 447. Europe Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 448. Europe Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 449. Europe Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 450. Europe Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 451. Germany Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 452. Germany Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 453. Germany Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 454. Germany Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 455. France Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 456. France Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 457. France Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 458. France Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 459. Italy Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 460. Italy Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 461. Italy Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 462. Italy Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 463. United Kingdom Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 464. United Kingdom Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 465. United Kingdom Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 466. United Kingdom Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 467. Netherlands Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 468. Netherlands Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 469. Netherlands Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 470. Netherlands Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 471. Rest of Europe Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 472. Rest of Europe Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 473. Rest of Europe Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 474. Rest of Europe Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 475. MEA Cancer API Sales, by Country K Tons (2023-2028)
  • Table 476. MEA Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 477. MEA Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 478. MEA Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 479. MEA Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 480. Middle East Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 481. Middle East Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 482. Middle East Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 483. Middle East Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 484. Africa Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 485. Africa Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 486. Africa Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 487. Africa Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 488. North America Cancer API Sales, by Country K Tons (2023-2028)
  • Table 489. North America Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 490. North America Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 491. North America Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 492. North America Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 493. United States Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 494. United States Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 495. United States Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 496. United States Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 497. Canada Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 498. Canada Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 499. Canada Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 500. Canada Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 501. Mexico Cancer API Sales, by Degib K Tons (2023-2028)
  • Table 502. Mexico Cancer API Sales, by Tinib K Tons (2023-2028)
  • Table 503. Mexico Cancer API Sales, by Rafenib K Tons (2023-2028)
  • Table 504. Mexico Cancer API Sales, by Parib K Tons (2023-2028)
  • Table 505. Research Programs/Design for This Report
  • Table 506. Key Data Information from Secondary Sources
  • Table 507. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer API: by Degib USD Million (2017-2022)
  • Figure 5. Global Cancer API: by Tinib USD Million (2017-2022)
  • Figure 6. Global Cancer API: by Rafenib USD Million (2017-2022)
  • Figure 7. Global Cancer API: by Parib USD Million (2017-2022)
  • Figure 8. South America Cancer API Share (%), by Country
  • Figure 9. Asia Pacific Cancer API Share (%), by Country
  • Figure 10. Europe Cancer API Share (%), by Country
  • Figure 11. MEA Cancer API Share (%), by Country
  • Figure 12. North America Cancer API Share (%), by Country
  • Figure 13. Global Cancer API: by Degib K Tons (2017-2022)
  • Figure 14. Global Cancer API: by Tinib K Tons (2017-2022)
  • Figure 15. Global Cancer API: by Rafenib K Tons (2017-2022)
  • Figure 16. Global Cancer API: by Parib K Tons (2017-2022)
  • Figure 17. South America Cancer API Share (%), by Country
  • Figure 18. Asia Pacific Cancer API Share (%), by Country
  • Figure 19. Europe Cancer API Share (%), by Country
  • Figure 20. MEA Cancer API Share (%), by Country
  • Figure 21. North America Cancer API Share (%), by Country
  • Figure 22. Global Cancer API share by Players 2022 (%)
  • Figure 23. Global Cancer API share by Players (Top 3) 2022(%)
  • Figure 24. Global Cancer API share by Players (Top 5) 2022(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Exelixis Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Exelixis Inc. (United States) Revenue: by Geography 2022
  • Figure 28. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 30. Eisai Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Eisai Ltd. (Japan) Revenue: by Geography 2022
  • Figure 32. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 34. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 36. F. Hoffman La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. F. Hoffman La Roche (Switzerland) Revenue: by Geography 2022
  • Figure 38. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 40. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 41. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 42. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 43. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 44. Ariad Pharmaceuticals Inc. (Takeda) (United States) Revenue, Net Income and Gross profit
  • Figure 45. Ariad Pharmaceuticals Inc. (Takeda) (United States) Revenue: by Geography 2022
  • Figure 46. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 47. Boehringer Ingelheim (Germany) Revenue: by Geography 2022
  • Figure 48. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 49. Celgene (United States) Revenue: by Geography 2022
  • Figure 50. Global Cancer API: by Degib USD Million (2023-2028)
  • Figure 51. Global Cancer API: by Tinib USD Million (2023-2028)
  • Figure 52. Global Cancer API: by Rafenib USD Million (2023-2028)
  • Figure 53. Global Cancer API: by Parib USD Million (2023-2028)
  • Figure 54. South America Cancer API Share (%), by Country
  • Figure 55. Asia Pacific Cancer API Share (%), by Country
  • Figure 56. Europe Cancer API Share (%), by Country
  • Figure 57. MEA Cancer API Share (%), by Country
  • Figure 58. North America Cancer API Share (%), by Country
  • Figure 59. Global Cancer API: by Degib K Tons (2023-2028)
  • Figure 60. Global Cancer API: by Tinib K Tons (2023-2028)
  • Figure 61. Global Cancer API: by Rafenib K Tons (2023-2028)
  • Figure 62. Global Cancer API: by Parib K Tons (2023-2028)
  • Figure 63. South America Cancer API Share (%), by Country
  • Figure 64. Asia Pacific Cancer API Share (%), by Country
  • Figure 65. Europe Cancer API Share (%), by Country
  • Figure 66. MEA Cancer API Share (%), by Country
  • Figure 67. North America Cancer API Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Exelixis Inc. (United States)
  • Pfizer Inc. (United States)
  • Eisai Ltd. (Japan)
  • Bristol-Myers Squibb (United States)
  • AbbVie Inc. (United States)
  • F. Hoffman La Roche (Switzerland)
  • AstraZeneca PLC (United Kingdom)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Ariad Pharmaceuticals Inc. (Takeda) (United States)
  • Boehringer Ingelheim (Germany)
  • Celgene (United States)
Additional players considered in the study are as follows:
Clovis Oncology (United States) , Eli Lilly & Company (United States) , Gilead Lifesciences Inc. (United States) , Incyte Corporation (United States) , Puma Biotech (United States) , TESARO, Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2023 232 Pages 50 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer API Market Quantitative research analysis
Global Cancer API Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Cancer API market are Exelixis Inc. (United States), Pfizer Inc. (United States), Eisai Ltd. (Japan), Bristol-Myers Squibb (United States), AbbVie Inc. (United States), F. Hoffman La Roche (Switzerland), AstraZeneca PLC (United Kingdom), Novartis AG (Switzerland), Bayer AG (Germany), Ariad Pharmaceuticals Inc. (Takeda) (United States), Boehringer Ingelheim (Germany) and Celgene (United States), to name a few.
"Upsurging Adoption of Offshore Manufacturing in Pharmaceutical Products Manufacturing " is seen as one of major influencing trends for Cancer API Market during projected period 2022-2028.

Know More About Global Cancer API Market Report?

Have a Query? Click Here

Other Related Reports

Gynecology Drugs Comprehensive Study by Therapeutics (Hormonal therapy, Non-Hormonal therapy), Prescription Mode (Prescription Based Drugs, OTC Drugs), Indication (Gynecology Cancers, Endometriosis...
$ 3650
Cough Suppressant Drugs Comprehensive Study by Type (Antitussives, Expectorants), Application (Healing of cough, Remedy for Flu), End-User (Hospitals, Diagnostic Clinics, Online Pharmacy, Retail Phar...
$ 3350
Cytotoxic Drug Comprehensive Study by Application (Breast Cancer, Blood Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other), Dosage (Injection, Solid Oral, Others) Players and Region - Global Ma...
$ 3500
Pharma & Cosmetics Comprehensive Study by Distribution Channel (Supermarket, Onlien Stores, Cosmetics Stores, Drug Stores), Cosmetics (Skincare, Haircare, Oral Care, Others), Pharmaceutical (Tablets,...
$ 3450
Contrast Agents Comprehensive Study by Type (Iodine-based, Barium-Sulfate, Gadolinium), Application (Interventional Radiology, Interventional Cardiology), Route of Administration (Intravenously/intra...
$ 3750
Skin Adhesives Comprehensive Study by Application (Ophthalmic Surgery, ENT Surgery, Dental Surgery, General Surgery, Plastic Surgery, Gynaecology, Gastroenterology, Orthopaedic, Surgical oncology, Ot...
$ 3650